NORETHINDRONE

Search structure
Trade Names:
Synonyms:
Status: Approved (1962)
Entry Type: Small molecule
Molecule Category: Parent Metabolite
UNII: T18F433X4S

Structure
InChI Key VIKNJXKGJWUCNN-XGXHKTLJSA-N
Smile C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
InChI
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H26O2
Molecular Weight 298.43
AlogP 3.49
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 0.0
Polar Surface Area 37.3
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 22.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Progesterone receptor agonist PubMed PubMed PubMed PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Secreted protein
- - 11 - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 1
- - 1 - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 2
- - 1 - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
2 3 0 2 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4
- 120 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 110
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 18460-45000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Menopause 3 D008593 ClinicalTrials
Sexual Dysfunction, Physiological 3 D012735 ClinicalTrials
Dysmenorrhea 3 D004412 ClinicalTrials
Endometriosis 3 D004715 ClinicalTrials
Pain 3 D010146 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Reperfusion Injury 2 D015427 ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting 2 D020529 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Hyperandrogenism 2 D017588 ClinicalTrials
Hepatitis C 1 D006526 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt
Salt
Mixture
Mixture
Mixture
Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Reproductive system and breast disorders
13.67
Injury, poisoning and procedural complications
10.42
Vascular disorders
9.74
General disorders and administration site conditions
9.61
Nervous system disorders
8.99
Gastrointestinal disorders
6.62
Psychiatric disorders
5.81
Skin and subcutaneous tissue disorders
4.06
Pregnancy, puerperium and perinatal conditions
3.75
Cardiac disorders
3.56
Endocrine disorders
3.18
Respiratory, thoracic and mediastinal disorders
2.56
Investigations
2.43
Musculoskeletal and connective tissue disorders
2.25
Hepatobiliary disorders
2.18
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.06

Cross References

Resources Reference
CAS NUMBER 68-22-4
ChEBI 7627
ChEMBL CHEMBL1162
DrugBank DB00717
DrugCentral 1962
EPA CompTox DTXSID9023380
FDA SRS T18F433X4S
Human Metabolome Database HMDB0014855
Guide to Pharmacology 2880
KEGG C05028
PDB NDR
PharmGKB PA450651
PubChem 6230
SureChEMBL SCHEMBL23390
ZINC ZINC000085205451
CONTENTS